Study #2014-0812
Assessment of the Tumor Response to Neoadjuvant Chemotherapy in Women with Invasive Breast Cancer using Tc99m sestamibi Molecular Breast Imaging: A Prospective Study.
MD Anderson Study Status
Not Accepting
Treatment Agent
Tc99m sestamibi
Description
This clinical trial studies technetium Tc-99m sestamibi molecular breast imaging in predicting tumor response in patients with locoregional breast cancer that has spread from where it began in the breast to surrounding normal tissue who are receiving neoadjuvant chemotherapy. Comparing results of diagnostic procedures, such as technetium Tc-99m sestamibi molecular breast imaging, done before, during, and after chemotherapy may help doctors predict a patient's response to treatment and help plan the best treatment.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Breast Cancer
Study phase:
Not applicable
Physician name:
Gaiane Rauch
Department:
Abdominal Imaging Department
For general questions about clinical trials:
1-855-996-1481
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.